Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ProQR Therapeutics NV EBITDA Margin % Related Terms
ProQR Therapeutics NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ProQR Therapeutics NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0PQ vs CRBP, NRXP, CRBU: EBITDA Margin % Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProQR Therapeutics NV (STU:0PQ) has a EBITDA Margin % of -637.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ProQR Therapeutics NV and its competitors. According to the industry distribution chart, ProQR Therapeutics NV ranks #627 out of 940 companies in the Biotechnology industry, placing it in the top 66.7%.
Is ProQR Therapeutics NV's EBITDA Margin % too high?
ProQR Therapeutics NV's current EBITDA Margin % is -637.24%. Based on the distribution chart, ProQR Therapeutics NV ranks #627 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's EBITDA Margin % compare to CRBP and NRXP?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #627 out of 940 companies for EBITDA Margin %. This places ProQR Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current EBITDA Margin % is -637.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, ProQR Therapeutics NV (STU:0PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.79, compared to a current price of €1.51 — trading 15.9% below its estimated fair value. The current EBITDA Margin % is -637.24%. ProQR Therapeutics NV's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ProQR Therapeutics NV (STU:0PQ), the current EBITDA Margin % is -637.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (STU:0PQ) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of €1.51 is trading 15.9% below its estimated GF Value™ of €1.79.
GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.
Key valuation signals for STU:0PQ:
EBITDA Margin %: -637.24%
GF Value™: €1.79 vs. price of €1.51 (15.9% below fair value)
No single metric tells the full story. See the STU:0PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
51GF Score
Get the complete analysis for STU:0PQ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0PQ has been successfully added to your 
